Sources and small print

1. Results are based on the STEP 1 Wegovy trial and SURMOUNT-1 Mounjaro trial, in which participants lost an average of 15% and 21% of their starting weight, respectively. Results vary – weight loss can be more or less than the average.

Wilding, J.P.H. et al. (2021) "Once-weekly semaglutide in adults with overweight or obesity" New England Journal of Medicine, 384(11)

https://doi.org/10.1056/NEJMoa2032183

Jastreboff, A.M. et al. (2022) "Tirzepatide Once Weekly for the Treatment of Obesity" New England Journal of Medicine, 387(3)

https://doi.org/10.1056/NEJMoa2206038

* An admin fee may apply for early cancellation. See our terms and conditions.

** Terms and conditions apply.